search

menu

  • Research Research
    • Where science meets inspired minds

    • Back
    • Research
    • Our Science
    • Research Groups
    • Facilities & Platforms
    • Clinical research
    • Find a researcher
    • Publications
    • Knowledge Transfer
  • Careers & study Careers & study
    • Become a leader in cancer research

    • Back
    • Careers & study
    • Vacancies
    • Faculty
    • Scientific staff
    • Scientific support staff
    • Postdoctoral fellows
    • PhD Students
    • Operational staff
    • Clinical fellows
    • Life in Amsterdam
    • Student internships
  • News & Events News & Events
    • Check out our stories and events

    • Back
    • News & Events
    • News
    • Media & Press
    • Calendar
  • About us About us
    • Maximum impact for cancer patients

    • Back
    • About us
    • Our vision
    • Organization
    • Collaborations
    • Responsible Research
    • Support us
    • Visit us
    • Contact us
  • Support us
Support us
  • Home
  • Publications
  • Research
  • Publications
  • Article

A cancer drug atlas enables synergistic targeting of independent drug vulnerabilities.

Ravi S Narayan ,
Piet Molenaar ,
Jian Teng ,
Fleur M G Cornelissen ,
Irene Roelofs ,
Renee Menezes ,
Rogier Dik ,
Tonny Lagerweij ,
Yoran Broersma ,
Naomi Petersen ,
Jhon Alexander Marin Soto ,
Eelke Brands ,
Philip van Kuiken ,
Maria C Lecca ,
Kristiaan J Lenos ,
Sjors G J G In 't Veld ,
Wessel van Wieringen ,
Frederick F Lang ,
Erik Sulman ,
Roel Verhaak ,
Brigitta G Baumert ,
Lucas J A Stalpers ,
Louis Vermeulen ,
Colin Watts ,
David Bailey ,
Ben J Slotman ,
Rogier Versteeg ,
David Noske ,
Peter Sminia ,
Bakhos A Tannous ,
Tom Wurdinger ,
Jan Koster ,
Bart A Westerman

Abstract

Personalized cancer treatments using combinations of drugs with a synergistic effect is attractive but proves to be highly challenging. Here we present an approach to uncover the efficacy of drug combinations based on the analysis of mono-drug effects. For this we used dose-response data from pharmacogenomic encyclopedias and represent these as a drug atlas. The drug atlas represents the relations between drug effects and allows to identify independent processes for which the tumor might be particularly vulnerable when attacked by two drugs. Our approach enables the prediction of combination-therapy which can be linked to tumor-driving mutations. By using this strategy, we can uncover potential effective drug combinations on a pan-cancer scale. Predicted synergies are provided and have been validated in glioblastoma, breast cancer, melanoma and leukemia mouse-models, resulting in therapeutic synergy in 75% of the tested models. This indicates that we can accurately predict effective drug combinations with translational value.

More about this publication

Nature communications

Volume 11
Issue nr. 1
Pages 2935
Publication date 10-06-2020

Full text links

Publisher website (DOI) 10.1038/s41467-020-16735-2
Europe PubMed Central 32523045
Pubmed 32523045

Where science meets inspired minds

Contact

Plesmanlaan 121
1066CX Amsterdam

020 512 9111 communicatie@nki.nl

Quick links

  • Vacancies
  • News
  • Contact us
  • Media & Press

Follow us on

Disclaimer
Privacy statement
Cookies
Change cookie settings

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.